<?xml version="1.0" encoding="UTF-8"?>
<table id="PMC7136878/table_4" xmlns="http://www.w3.org/1999/xhtml">
 <caption>
  <label>Table 4</label>
  <p>List of potential drug interactions and reactions. 
   <a rid="bib16" ref-type="bibr">
    <sup>16</sup>
   </a>
   <sup>,</sup>
   <a rid="bib17" ref-type="bibr">
    <sup>17</sup>
   </a>
  </p>
 </caption>
 <thead>
  <tr>
   <th colspan="1" rowspan="1" id="0-0-.">Drugs</th>
   <th colspan="1" rowspan="1" id="0-1-.">Combined drugs</th>
   <th colspan="1" rowspan="1" id="0-2-.">Risk</th>
  </tr>
 </thead>
 <tbody>
  <tr>
   <td align="left" rowspan="9">Lopinavir/Ritonavir</td>
   <td align="left">HMG-CoA reductase inhibitors.</td>
   <td align="left">Simvastatin is not recommended combination. Atorvastatin is recommended under carefully monitoring.</td>
  </tr>
  <tr>
   <td align="left">Sedative-hypnotics</td>
   <td align="left">Combination is not recommended: midazolam, triazolam.</td>
  </tr>
  <tr>
   <td align="left">Extracts of St John's wort (Hypericum perforatum L.)</td>
   <td align="left">Combination is not recommended. Combined usage may reduce the efficacy.</td>
  </tr>
  <tr>
   <td align="left">Dihydropyridine Calcium Channel Blockers</td>
   <td align="left">Careful combination. It may lead to the increase of plasma concentration of dihydropyridine calcium channel blockers</td>
  </tr>
  <tr>
   <td align="left">Oral anticoagulants</td>
   <td align="left">During the joint use of warfarin, it is recommended to monitor the INR(international normalized ratio).</td>
  </tr>
  <tr>
   <td align="left">Amiodarone</td>
   <td align="left">Careful combination. It may increase the plasma concentration of amiodarone, and the heart rate should be monitored.</td>
  </tr>
  <tr>
   <td align="left">Triazoles</td>
   <td align="left">Combination is not recommended: voriconazole and high-dose itraconazole(&gt;200mg/d)</td>
  </tr>
  <tr>
   <td align="left">Immunosuppressant</td>
   <td align="left">Careful combination. It may increase the plasma concentration of immunosuppressant. It is recommended to monitor the concentration of immunosuppressant.</td>
  </tr>
  <tr>
   <td align="left">Antiepileptic drugs</td>
   <td align="left">Combination is not recommended: sodium valproate, lamotrigine. It may be better to adjust the drug dosage according to the blood concentration.</td>
  </tr>
  <tr>
   <td align="left" rowspan="3">Ribavirin</td>
   <td align="left">Lamivudine</td>
   <td align="left">Careful combination. May cause fatal or non-fatal lactic acidosis.</td>
  </tr>
  <tr>
   <td align="left">Zidovudine</td>
   <td align="left">Careful combination. May reduce the effect of zidovudine.</td>
  </tr>
  <tr>
   <td align="left">Didanosine</td>
   <td align="left">May cause lactic acidosis, liver injury, peripheral neuropathy and pancreatitis.</td>
  </tr>
  <tr>
   <td align="left" rowspan="2">Interferons</td>
   <td align="left">Theophylline</td>
   <td align="left">The clearance of theophylline may be reduced. It is recommended to monitor the plasma concentration of theophylline and adjust the dosage of theophylline properly during the combined use.</td>
  </tr>
  <tr>
   <td align="left">Hepatotoxic drugs</td>
   <td align="left">Combined with antiepileptics, erythromycin, minocycline and other hepatotoxic drugs may rise potential risk of liver injury.</td>
  </tr>
 </tbody>
</table>
